Shahid Ashfaque
Impact in
-
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
-
- Brain Metastases and Treatment
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 7
- Cancer Treatment and Pharmacology 6
- HER2/EGFR in Cancer Research 4
- Peptidase Inhibition and Analysis 1
-
- Advanced Breast Cancer Therapies 2
- Brain Metastases and Treatment 2
- Lung Cancer Treatments and Mutations 1
- Co-authors
- Wěi Li (4 shared papers)Anton Egorov (6 shared papers)Javier Cortés (5 shared papers)Sara A. Hurvitz (3 shared papers)Kan Yonemori (2 shared papers)Thomas Bachelot (2 shared papers)Giampaolo Bianchini (2 shared papers)Hiroji Iwata (3 shared papers)
- Journals
- Annals of Oncology (2 papers)ESMO Open (2 papers)Journal of Clinical Oncology (1 paper)Nature Medicine (1 paper)Cancer Research (1 paper)
- Partner nations
- JapanSouth KoreaUnited States
In The Last Decade
Shahid Ashfaque
7 papers receiving 106 citations
Shahid Ashfaque's Hit Papers
Peers
Comparison fields: 5 of 16
- Oncology 92
- Pulmonary and Respiratory Medicine 54
- Cancer Research 18
- Radiology, Nuclear Medicine and Imaging 22
- Genetics 8
Countries citing papers authored by Shahid Ashfaque
This map shows the geographic impact of Shahid Ashfaque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shahid Ashfaque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shahid Ashfaque more than expected).
Fields of papers citing papers by Shahid Ashfaque
This network shows the impact of papers produced by Shahid Ashfaque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shahid Ashfaque. The network helps show where Shahid Ashfaque may publish in the future.
Co-authors
The 25 scholars most cited alongside Shahid Ashfaque, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Hit paper breakdown → | 2024 | 53 |
| 2 | 2023 | 24 | |
| 3 | 2024 | 15 | |
| 4 | 2023 | 7 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 1 |
About Shahid Ashfaque
Shahid Ashfaque is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Infectious Diseases, having authored 7 papers that have together received 107 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers), Breast Cancer Treatment Studies (4 papers), Advanced Breast Cancer Therapies (2 papers), Brain Metastases and Treatment (2 papers), Radiopharmaceutical Chemistry and Applications (1 paper), Lung Cancer Treatments and Mutations (1 paper) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Oncology (92 citations), Pulmonary and Respiratory Medicine (54 citations), Cancer Research (18 citations), Radiology, Nuclear Medicine and Imaging (22 citations) and Genetics (8 citations). Shahid Ashfaque has collaborated with scholars based in Japan, South Korea and United States. Frequent co-authors include Wěi Li, Anton Egorov, Javier Cortés, Sara A. Hurvitz, Kan Yonemori, Thomas Bachelot, Giampaolo Bianchini, Hiroji Iwata, Seock‐Ah Im and Giuseppe Curigliano. Their work appears in journals such as Annals of Oncology, ESMO Open, Journal of Clinical Oncology, Nature Medicine and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.